Role of bone-modifying agents in the treatment of bone metastasis in lung cancer
Currently,the medical treatment drugs recommended by various guidelines for bone metastasis of malignant tumors are mainly bone-modifying agent,which are divided into desuzumab and bisphosphonate drugs,and these two kinds of drugs are also approved to be used in the treatment of hypercalcemia and osteoporosis.Bisphosphonate drugs have been used in clinic for a long time,with wide applicationed and many varieties.At present,they are divided into three generations,and each generation has different representative drugs,such as the first generation of etidronate chlorophosphonate,the second generation of pamidronate disodium,the third generation of zoledronic acid and so on.Lung cancer is a tumor with a high incidence globally.Most patients are in the advanced stage when they see a doctor,and about half of them show bone metastasis,a huge burden to patients quality of life.Therefore,once the bone metastasis of lung cancer is clearly diagnosed,bone-modifying agent should be used as soon as possible.This article reviewed the application of bone-improving drugs for bone metastasis in lung cancer.
NETL
NSTL
万方数据
